Moving forward with new data and approaches: A fresh look at anthracyclines in non-Hodgkin's lymphoma

Dino Amadori

Research output: Contribution to journalArticle

Abstract

Anthracyclines have a central role in the management of non-Hodgkin's lymphoma (NHL). The cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) treatment regimen has been the standard of care for more than 20 years. Further improvements have been made to the efficacy of this chemotherapy by reducing the dosing interval and adding rituximab to the regimen. A major limitation to the use of anthracyclines is the development of cardiotoxicity as a late adverse event. Strategies to reduce cardiac events include changes to the dosing schedule for doxorubicin, use of the chelating agent dexrazoxane and the use of liposome-encapsulated doxorubicin. This latter strategy has demonstrated good efficacy and reduced cardiotoxicity in patients with NHL, including those at risk of developing cardiac effects.

Original languageEnglish
Pages (from-to)1-3
Number of pages3
JournalHematology Reports
Volume3
Issue number3 SUPPL.
DOIs
Publication statusPublished - 2011

Keywords

  • Anthracycline
  • Doxorubicin
  • Liposomal doxorubicin
  • Non-Hodgkin's lymphoma

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Moving forward with new data and approaches: A fresh look at anthracyclines in non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

  • Cite this